HomeNewsBusinessCompaniesMoody's assigns first-time B3 ratings to OYO, outlook stable

Moody's assigns first-time B3 ratings to OYO, outlook stable

The rating incorporates Moody's expectation that OYO will continue to incur losses over the next 2-3 years and that its path to profitability remains uncertain in light of travel restrictions due to the pandemic.

May 20, 2021 / 20:48 IST
Story continues below Advertisement
Representative image
Representative image

Moody's Investors Service has assigned a first-time B3 corporate family rating (CFR) to Oravel Stays Private Limited (OYO), the business rating agency said in a statement issued on May 20.

Moody's has simultaneously assigned a B3 rating to the "senior secured term loan" to be issued by Oravel Stays Singapore Pte. Ltd, OYO's wholly owned subsidiary. The proposed loan will be guaranteed by OYO and many of its subsidiaries, the agency said.

Story continues below Advertisement

"The outlook is stable," it further stated, noting that "the company will use the loan proceeds to refinance its debt and for general corporate purposes."

Moody's Analyst Sweta Patodia said OYO's B3 corporate family rating "reflects its position as one of the largest providers of budget accommodation in its key operating markets".

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show